Brian Mendelsohn
Independent Consultant Exelixis, Inc.
Brian A. Mendelsohn, Principal at MBC Consulting, is an accomplished researcher in the field of antibody drug conjugates. Brian started exploring ADCs in 2000 with Seattle Genetics, where he first synthesized the MMAE and MMAF payloads. Working across drug-development from discovery to manufacturing, he developed novel ADCs, ADC linker-payloads and conjugation technologies at Agensys, Ajinomoto Bio-Pharma Services, and Exelixis. Brian has published more than 40 scientific manuscripts and received accolades for contributions to the field of ADCs: Heroes of Chemistry by the American Chemical Society for developing Adcetris® in 2018, and the George R Pettit Individual Input to the Field for 2023 at World ADC.
Seminars
ADCs have become increasingly sophisticated. Payload selection, linker design, and conjugation chemistries are critical to enhancing efficacy, addressing clinical resistance, and improving the therapeutic index. Join this workshop to explore emerging payload classes, advances in linker design, next-generation conjugation technologies, and dual-payload strategies across ADCs and beyond.
This workshop will explore advances in conjugation chemistry and their implications for ADC design, drug-to-antibody ratio (DAR), and therapeutic properties.
Key Topics Include:
- Unlocking novel conjugation, linker design and payloads with established and novel mechanisms of action
- Unravelling dual-payload ADCs, and bioconjugates designs beyond ADCs
